Aylar POYRAZ, Avni SARAÇ, Kemali BAYKANER, Ferda ALPASLAN PINARLI, İrem DOĞAN, Aynur OĞUZ, Ceyda KARADENİZ, Abdullah EKMEKÇİ, Arzu OKUR, Faruk GÜÇLÜ PINARLI

Mutational Screening of miR-17-92 Cluster and miR-34a by DNA Sequencing in Childhood High-Grade Brain Tumors

OBJECTIVEThe miR-17-92 cluster and miR-34a are short non-coding RNAs, which are important in tumorigenesisas they regulate numerous oncogenes and tumor suppressor genes. This study aimed to investigate theassociations of mutations/polymorphisms of the miR-17-92 cluster and miR-34a coding sequences withhigh-grade central nervous system malignancies in pediatric patients.METHODSThis study included 53 children with central nervous system malignancies and age- and gender-matched27 healthy volunteers. Genomic DNAs were extracted from the paraffin-embedded tumor tissues (n=53)and peripheral blood samples (n=15) in the patient group and from the peripheral blood samples in thecontrol group and were analyzed for mutations/polymorphisms of the miR-17-92 cluster and miR-34acoding sequences by DNA sequencing method.RESULTSThere were no copy number alterations, amplifications, deletions, insertions, duplications, rearrangements, single nucleotide polymorphisms or mutations in the miR-17-92 cluster and miR-34a coding sequences of tumor tissue or blood samples in the patient group and of blood samples in the control group.CONCLUSIONIn children with high-grade brain tumors, no mutation was detected, leading to failures in regulations ofmiRNA coding DNA sequences of miR-17-92 and miR-34a. Further studies are needed to elucidate extremely complicated mechanisms underlying oncogenesis in high-grade central nervous system tumors.

PDF

___

1. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 2010;466(7308):835–40.
2. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010;11:597–610.
3. Slaby O, Bienertova-Vasku J, Svoboda M, Vyzula R. Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. Cell Mol Med 2012;16:8–21.
4. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101(9):2999–3004.
5. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167–79.
6. Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ 2010;17(2):193–9.
7. Chen F, Hu SJ. Effect of microRNA-34a in cell cycle, differentiation, and apoptosis: a review. J Biochem Mol Toxicol 2012;26(2):79–86.
8. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 2005;11(3):1119–28.
9. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 2009;69(19):7569–76.
10.Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle 2010;9(6):1031–6.
11.Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008;133(2):217–22.
12.Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 2008;132(5):875–86.
13.Olive V, Jiang I, He L. mir-17-92, a cluster of miRNAs in the midst of the cancer network. Int J Biochem Cell Biol 2010;42(8):1348–54.
14.He L, Thomson JM, Hemann MT, HernandoMonge E, Mu D, Goodson S, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435(7043):828–33.
15.O’Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435(7043):839–43.
16.Northcott PA, Fernandez LA, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, et al. The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 2009;69(8):3249–55.
17.Uziel T, Karginov FV, Xie S, Parker JS, Wang YD, Gajjar A, et al. The miR-17~92 cluster collaborates with the Sonic Hedgehog pathway in medulloblastoma. Proc Natl Acad Sci U S A 2009;106(8):2812–7.
18.Pinarli FG, Oguz A, Karadeniz C, Okur A, Sarac A, Baykaner K, et al. Institutional experience of paediatric high-grade central nervous system tumours: an analysis of 74 patients and review of the literature. Contemp Oncol (Pozn) 2012;16(1):26–33.
19.Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60
20.Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009;10(3):399–416.
21.Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10(6):389–402.
22.Meltzer PS. Cancer genomics: small RNAs with big impacts. Nature 2005;435(7043):745–6.
23.Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6(11):857–66.
24.Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, et al. microRNA profiling identifies cancerspecific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009;15(17):5560–8.
25.Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99(24):15524–9.
26.Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102(39):13944–9.
27.Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC, et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007;109(12):5079–86.
28.Deng S, Calin GA, Croce CM, Coukos G, Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008;7(17):2643–6.
29.Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mutat Res 2011;717(1-2):1–8.
30.Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, et al. Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 2012;33(1):254–63.
31.Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012;4(3):143–59.
32.Mueller S, Chang S. Pediatric brain tumors: current treatment strategies and future therapeutic approaches. Neurotherapeutics 2009;6(3):570–86.
33.Pollack IF. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 2011;8(2):135–48.
34.Monje M, Beachy PA, Fisher PG. Hedgehogs, flies, Wnts and MYCs: the time has come for many things in medulloblastoma. J Clin Oncol 2011;29(11):1395–8.
35.Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123(4):465–72.
36.Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011;29(11):1408–14.
37.Remke M, Hielscher T, Korshunov A, Northcott PA, Bender S, Kool M, et al. FSTL5 is a marker of poor prognosis in non-WNT/non-SHH medulloblastoma. J Clin Oncol 2011;29(29):3852–61.
38.Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011;29(11):1424–30.
39.Lavon I, Zrihan D, Granit A, Einstein O, Fainstein N, Cohen MA, et al. Gliomas display a microRNA expression profile reminiscent of neural precursor cells. Neuro Oncol 2010;12(5):422–33.
40.Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of highgrade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9(3):157–73.
41.The Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455(7216):1061–8.
42. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, et al. Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 2010;28(18):3061–8.
43.Fangusaro J. Pediatric high grade glioma: a review and update on tumor clinical characteristics and biology. Front Oncol 2012;2:105.
44.Jones C, Perryman L, Hargrave D. Paediatric and adult malignant glioma: close relatives or distant cousins? Nat Rev Clin Oncol 2012;9(7):400–13.
45.Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, et al. miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 2013;32(9):1155–63.
46.Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci U S A 2008;105(36):13421–6.
47.Mandke P, Wyatt N, Fraser J, Bates B, Berberich SJ, Markey MP. MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame. PLoS One 2012;7(8):e42034.
48.Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, et al. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 2010;17(2):236–45.
49.Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 2010;70(14):5923–30.